Gilead Sciences
About Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company headquartered in Foster City, California, a global leader in antiviral therapies for HIV and hepatitis, plus a growing oncology franchise.
Leadership Team
Leadership as listed on gilead.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on gilead.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Virology
Core therapeutic area, including HIV and liver disease medicines.
Source: gilead.comSites in Ireland
Carrigtohill, Co. Cork
IDA Business & Technology Park site handling manufacturing, quality control, packaging, release and distribution.
Source: gilead.comDublin
North Wall Quay office hosting Gilead's global Pediatric Centre of Excellence.
Source: gilead.comSites as listed on gilead.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Pipeline & Regulatory Record
What public registers list for Gilead Sciences: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 22 Nov 2026.
Clinical trials 70 in our ClinicalTrials.gov registers · 5 in the EU register
Showing 10 of 70, trials with Irish sites first. The full lists are on the sponsor pages below.
All trials by sponsor name 1 registry name
Drugs in these trials 54 compounds
EU trials register (CTIS) 5 authorised or ongoing
- Study of GS-5319 in Adults With Solid Tumors2025-522397-36-00 · Phase I · Ongoing
- A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens2025-524336-19-00 · Phase III · Ongoing
- A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy2025-524335-39-00 · Phase III · Ongoing
- An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination with Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-12026-526026-40-00 · Phase III · Ongoing
- A Multicenter First-in-human Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the 5T4 Antibody-Drug Conjugate TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)2025-522517-35-00 · Phase I/II · Ongoing
Medicine shortages 3 in the FDA list
- Emtricitabine Oral SolutionUS (FDA) · resolved · updated 17 Jun 2026
- Emtricitabine CapsuleUS (FDA) · resolved · updated 17 Jun 2026
- Idelalisib TabletUS (FDA) · resolved · updated 7 Apr 2026
A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.
NICE technology appraisals 11 of its medicines · 11 current
- Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)NICE TA1089 · Terminated (no company submission) · 13 Aug 2025
- Remdesivir and tixagevimab plus cilgavimab for treating COVID-19NICE TA971 · Optimised, Not recommended · 8 May 2024
- Bulevirtide for treating chronic hepatitis DNICE TA896 · Optimised · 7 Jun 2023
- Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesNICE TA819 · Recommended · 17 Aug 2022
- Idelalisib for treating refractory follicular lymphomaNICE TA604 · Not recommended · 2 Oct 2019
- Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis CNICE TA507 · Optimised · 21 Feb 2018
- Sofosbuvir–velpatasvir for treating chronic hepatitis CNICE TA430 · Optimised · 25 Jan 2017
- Ledipasvir–sofosbuvir for treating chronic hepatitis CNICE TA363 · Optimised · 25 Nov 2015
Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Group (Gilead Sciences): founded 1987, headquarters Foster City, website gilead.com. Wikidata Q663596 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.
How this is matched: register records are linked to this page by the organisation name they carry, here Gilead Sciences; Gilead Sciences Inc.; Gilead Sciences Ireland UC; Gilead Sciences Ireland Unlimited Company; Gilead Sciences, Inc.; GILEAD and 1 more. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports Gilead Sciences, Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $29.44bn | $5.80bn | 19.7% | $8.51bn | 10-K 2026 |
| Dec 2024 | $28.75bn | $5.91bn | 20.5% | $480m | 10-K 2026 |
| Dec 2023 | $27.12bn | $5.72bn | 21.1% | $5.67bn | 10-K 2026 |
| Dec 2022 | $27.28bn | $4.98bn | 18.2% | $4.59bn | 10-K 2025 |
| Dec 2021 | $27.31bn | $4.60bn | 16.9% | $6.23bn | 10-K 2024 |
R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.
Companies registered in Ireland 4 active in the CRO register
| Company | CRO no. | Registered | Last accounts |
|---|---|---|---|
| Gilead Sciences Ireland Unlimited Company ULC - Private Unlimited Company · LEI 5493003MQVQXRKDWOH85 | 259755 | 1997 | Dec 2024 |
| Gilead Biopharmaceutics Ireland Unlimited Company ULC - Private Unlimited Company | 316876 | 1999 | Dec 2025 |
| Gilead Apollo Unlimited Company ULC - Private Unlimited Company | 586804 | 2016 | Dec 2025 |
| Gilead Therapeutics A1 Unlimited Company ULC - Private Unlimited Company · LEI 5493008JS57WSQRPX760 | 615395 | 2017 | Dec 2025 |
From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Gilead Sciences, Inc. as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.